Can bosentan reverse lung artery thickening? small study investigates

NCT ID NCT00595049

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether bosentan (Tracleer) can reduce the thickness of lung artery walls in people with a type of high blood pressure in the lungs (pulmonary arterial hypertension, or PAH). Eleven adults with PAH took bosentan for 6 months. Researchers measured artery wall thickness and how well small blood vessels in the lungs responded to natural chemicals. The goal was to see if the drug could improve artery structure and function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION, PULMONARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Royal Prince Alfred Hospital

    Camperdown, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.